Alkermes plc $ALKS Position Boosted by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its position in Alkermes plc (NASDAQ:ALKS) by 10.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 322,748 shares of the company’s stock after buying an additional 30,801 shares during the quarter. Fisher Asset Management LLC owned approximately 0.20% of Alkermes worth $9,682,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Alkermes by 117.2% in the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock worth $9,098,000 after acquiring an additional 148,696 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in Alkermes during the first quarter worth $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Alkermes by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after purchasing an additional 20,091 shares during the period. Envestnet Asset Management Inc. increased its stake in Alkermes by 1.3% during the second quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock valued at $1,249,000 after purchasing an additional 551 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Alkermes by 2.0% during the second quarter. Teacher Retirement System of Texas now owns 42,215 shares of the company’s stock valued at $1,208,000 after purchasing an additional 816 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Wall Street Analyst Weigh In

ALKS has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their price target on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Wall Street Zen lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Bank of America lifted their target price on Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. HC Wainwright reaffirmed a “neutral” rating and set a $43.00 target price on shares of Alkermes in a report on Thursday, February 26th. Finally, Wells Fargo & Company raised their price target on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Trading Up 0.3%

NASDAQ ALKS opened at $29.28 on Thursday. The company has a 50-day moving average price of $31.60 and a two-hundred day moving average price of $30.24. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $36.32. The stock has a market cap of $4.88 billion, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 7.28 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the prior year, the firm posted $1.05 earnings per share. The business’s quarterly revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, equities research analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Shane Cooke sold 61,200 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares in the company, valued at $3,586,430.08. This represents a 37.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $29.29, for a total transaction of $59,575.86. Following the sale, the executive vice president owned 237,660 shares in the company, valued at $6,961,061.40. This trade represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 157,434 shares of company stock worth $5,305,794. 4.40% of the stock is owned by company insiders.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.